Clinical Trials

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (H-30956) (H-30956)

Women diagnosed with stage I - III ER positive breast cancer that are currently taking adjuvant Aromatase Inhibitor (AI) therapy and have experienced vaginal dryness or vaginitis symptoms are invited to participate in a study comparing Estring vaginal estrogen to Replens vaginal cream. If interested please call (713) 798-7315.

For study details see REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy.